Molecular docking and simulation studies of FDA approved drugs targeting Allosteric inhibition of Glycogen synthase kinase-3β
DOI:
https://doi.org/10.35516/jjps.v19i2.2906Abstract
Background: Inhibition of glycogen synthase kinase (GSK-3β) by various mechanisms of inhibition has become an important drug target for treating neurodegenerative diseases such as Alzheimer’s disease (AD). AD is characterized by cognitive, memory loss, and behavioral impairments. The pathological hallmarks of AD which appear before the clinical symptoms are neurofibrillary tangles and amyloid plaques.
Aim and Objectives: In the present study, we focused on the in-silico-based prediction approach for the virtual screening of FDA-approved ligands (Drug bank database) to target the allosteric pocket of GSK-3β, with the help of Schrodinger (Maestro software).
Results and Conclusion: After various levels of screening compounds, out of 2133 FDA-approved ligands, only three compounds formoterol, salmeterol, and polydatin were subjected to induced fit docking (IFD). After performing IFD, one top pose of the above three compounds was proposed for molecular dynamics studies by using the Desmond module. Formoterol showed the most stable interactions with the key amino acid residues. However, further to confirm these finding experimental studies are required.
References
Bomasang-Layno E, Bronsther R. Diagnosis and Treatment of Alzheimer’s Disease: An Update. Delaware J Public Heal. 2021;7(4). DOI: https://doi.org/10.32481/djph.2021.09.009
Valencia E. FireScholars ELUCIDATING THE ROLE OF O-GLCNACYLATION AND GSK3B IN ALZHEIMER ’ S DISEASE. 2022;
Ugbaja SC, Lawal IA, Abubakar BH, Mushebenge AG, Lawal MM, Kumalo HM. Allostery Inhibition of BACE1 by Psychotic and Meroterpenoid Drugs in Alzheimer’s Disease Therapy. Molecules. 2022;27(14). DOI: https://doi.org/10.3390/molecules27144372
Bradley D, Beltrao P. Evolution of protein kinase substrate recognition at the active site. PLoS Biol. 2019;17(6):1–25. DOI: https://doi.org/10.1371/journal.pbio.3000341
Sunkari YK, Meijer L, Flajolet M. The protein kinase CK1: Inhibition, activation, and possible allosteric modulation. Front Mol Biosci. 2022;9(August):1–10. DOI: https://doi.org/10.3389/fmolb.2022.916232
Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev. 2002;22(4):373–84. DOI: https://doi.org/10.1002/med.10011
Wei J, Wang J, Zhang J, Yang J, Wang G, Wang Y. Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity. Eur J Med Chem [Internet]. 2022;236:114301. Available from: https://doi.org/10.1016/j.ejmech.2022.114301 DOI: https://doi.org/10.1016/j.ejmech.2022.114301
Pandey MK, DeGrado TR. Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging [Internet]. Vol. 6, Theranostics. Ivyspring International Publisher; 2016 [cited 2021 Apr 14]. p. 571–93. Available from: /pmc/articles/PMC4775866/ DOI: https://doi.org/10.7150/thno.14334
Di Fruscia P, Edfeldt F, Shamovsky I, Collie GW, Aagaard A, Barlind L, et al. Fragment-Based Discovery of Novel Allosteric MEK1 Binders. ACS Med Chem Lett. 2021;12(2):302–8. DOI: https://doi.org/10.1021/acsmedchemlett.0c00563
Balboni B, Tripathi SK, Veronesi M, Russo D, Penna I, Giabbai B, et al. Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays. Int J Mol Sci. 2022;23(7). DOI: https://doi.org/10.3390/ijms23073856
Lu X, Smaill JB, Ding K. New Promise and Opportunities for Allosteric Kinase Inhibitors. Angew Chemie - Int Ed. 2020;59(33):13764–76. DOI: https://doi.org/10.1002/anie.201914525
Morales-Garcia JA, Luna-Medina R, Alonso-Gil S, Sanz-Sancristobal M, Palomo V, Gil C, et al. Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. ACS Chem Neurosci. 2012;3(11):963–71. DOI: https://doi.org/10.1021/cn300110c
Martínez-González L, Gonzalo-Consuegra C, Gómez-Almería M, Porras G, de Lago E, Martín-Requero Á, et al. Tideglusib, a non-atp competitive inhibitor of gsk-3as a drug candidate for the treatment of amyotrophic lateral sclerosis. Int J Mol Sci. 2021;22(16). DOI: https://doi.org/10.3390/ijms22168975
Rico A, Guembelzu G, Palomo V, Martínez A, Aiastui A, Casas‐fraile L, et al. Allosteric modulation of GSK‐3β as a new therapeutic approach in limb girdle muscular dystrophy R1 Calpain 3‐related. Int J Mol Sci. 2021;22(14):1–18. DOI: https://doi.org/10.3390/ijms22147367
Bertrand JA, Thieffine S, Vulpetti A, Cristiani C, Valsasina B, Knapp S, et al. Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors. J Mol Biol [Internet]. 2003 Oct 17 [cited 2021 Apr 30];333(2):393–407. Available from: https://pubmed.ncbi.nlm.nih.gov/14529625/ DOI: https://doi.org/10.1016/j.jmb.2003.08.031
Satarker S, Maity S, Mudgal J, Nampoothiri M. In silico screening of neurokinin receptor antagonists as a therapeutic strategy for neuroinflammation in Alzheimer’s disease. Mol Divers [Internet]. 2022;26(1):443–66. Available from: https://doi.org/10.1007/s11030-021-10276-6 DOI: https://doi.org/10.1007/s11030-021-10276-6
Chauhan N, Gajjar A. Classifying druggability on potential binding sites of glycogen synthase kinase-3β: An in-silico assessment. Acta Pharm Sci. 2017;55(3):43–60. DOI: https://doi.org/10.23893/1307-2080.APS.05518
Ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J. Structure of GSK3β reveals a primed phosphorylation mechanism. Nat Struct Biol [Internet]. 2001 [cited 2021 Apr 14];8(7):593–6. Available from: https://pubmed.ncbi.nlm.nih.gov/11427888/ DOI: https://doi.org/10.1038/89624
Silva GM, Borges RS, Santos KLB, Federico LB, Francischini IAG, Gomes SQ, et al. Revisiting the Proposition of Binding Pockets and Bioactive Poses for GSK-3β Allosteric Modulators Addressed to Neurodegenerative Diseases. Int J Mol Sci [Internet]. 2021 Jul 31;22(15):8252. Available from: https://www.mdpi.com/1422-0067/22/15/8252 DOI: https://doi.org/10.3390/ijms22158252
Palomo V, Soteras I, Perez DI, Perez C, Gil C, Campillo NE, et al. Exploring the Binding Sites of Glycogen Synthase Kinase 3. Identification and Characterization of Allosteric Modulation Cavities. J Med Chem [Internet]. 2011 Dec 22;54(24):8461–70. Available from: https://pubs.acs.org/doi/10.1021/jm200996g
Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27(3):221–34. DOI: https://doi.org/10.1007/s10822-013-9644-8
Bowers KJ, Chow E, Xu H, Dror RO, Eastwood MP, Gregersen BA, et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. Proc 2006 ACM/IEEE Conf Supercomput SC’06. 2006;(November). DOI: https://doi.org/10.1145/1188455.1188544
Mangala K, Vinayak W, Aasiya C, Chandrakant B, Amol M, Kumar D, et al. Reconnoitering imidazopyridazines as anticancer agents based on virtual modelling approach: quantitative structure activity relationship, molecular docking and molecular dynamics. J Biomol Struct Dyn [Internet]. 2023;0(0):1–18. Available from: https://doi.org/10.1080/07391102.2023.2204502 DOI: https://doi.org/10.1080/07391102.2023.2204502
Palomo V, Soteras I, Perez DI, Perez C, Gil C, Campillo NE, et al. Exploring the binding sites of glycogen synthase kinase 3. identification and characterization of allosteric modulation cavities. J Med Chem [Internet]. 2011 Dec 22 [cited 2021 Apr 30];54(24):8461–70. Available from: https://pubs.acs.org/doi/abs/10.1021/jm200996g DOI: https://doi.org/10.1021/jm200996g
Tolosa E, Litvan I, Höglinger GU, Burn DJ, Lees A, Andrés M V., et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29(4):470–8. DOI: https://doi.org/10.1002/mds.25824
Höglinger GU, Huppertz HJ, Wagenpfeil S, Andrés M V., Belloch V, León T, et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord. 2014;29(4):479–87. DOI: https://doi.org/10.1002/mds.25815
Zhang P, Li S, Gao Y, Lu W, Huang K, Ye D, et al. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake. Bioorg Med Chem Lett [Internet]. 2014 Dec;24(24):5639–43. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0960894X14011494 DOI: https://doi.org/10.1016/j.bmcl.2014.10.078
Zhang P, Hu HR, Bian SH, Huang ZH, Chu Y, Ye DY. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β). Eur J Med Chem [Internet]. 2013;61:95–103. Available from: http://dx.doi.org/10.1016/j.ejmech.2012.09.021 DOI: https://doi.org/10.1016/j.ejmech.2012.09.021
Palomo V, Perez DI, Roca C, Anderson C, Rodríguez-Muela N, Perez C, et al. Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. J Med Chem. 2017;60(12):4983–5001. DOI: https://doi.org/10.1021/acs.jmedchem.7b00395
Downloads
Published
How to Cite
Issue
Section
Accepted 2025-02-20
Published 2026-03-17
